• Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status
Opinion provided by Committee for Medicinal Products for Human Use


EMA’s human medicines committee (CHMP) has confirmed its recommendation to suspend the marketing authorisations of several generic medicines tested by Synchron Research Services, a contract research organisation (CRO) located in Ahmedabad, India. This concludes the re-examination requested by the marketing authorisation holders for some of the medicines concerned.

The CHMP adopted its initial recommendation in May 2022, after irregularities were found in how the CRO carried out bioequivalence studies, which raised serious concerns about the company’s quality management system and the reliability of data from that site. Bioequivalence studies are conducted to show that a generic medicine releases the same amount of active substance in the body as the reference medicine. The CHMP concluded that for the majority of the medicines investigated no adequate bioequivalence data were available from other sources and therefore recommended that they be suspended. For a small number of authorised generic medicines, adequate bioequivalence data were available from other sources, and these medicines were allowed to remain on the EU market.

During the re-examination, the CHMP identified that adequate bioequivalence data are available from an alternative study for eight medicines. The marketing authorisations for these medicines can therefore be maintained1.

As a result of the CHMP’s initial opinion and re-examination, the recommendation to suspend around 100 medicines for which adequate bioequivalence data are lacking is confirmed. To lift the suspension, companies must provide alternative data demonstrating bioequivalence. Medicines for which ongoing marketing authorisation applications rely solely on data from Synchron Research Services will not be granted authorisation in the EU. An updated list of the medicines concerned by the procedure is available on the EMA website.

Some of the medicines that have been recommended for suspension may be of critical importance (e.g. due to lack of available alternatives) in a given EU Member State and national authorities can therefore temporarily postpone the suspension in the interest of patients. Member States should also decide whether recalls of the affected medicines are needed in their territories.

EMA and national authorities will continue working closely together to ensure that studies on EU medicines are carried out to the highest standards and that companies comply with all aspects of good clinical practice (GCP). If companies do not meet required standards, authorities will take whatever measures necessary to ensure the integrity of data used to approve EU medicines.

The CHMP's recommendation will now be sent to the European Commission which will issue a legally binding decision in due course.

1 Diuver, Torasemide Teva, Torasemid AL, Torasemid-ratiopharm, Torasemid STADA, Torasemide and Torasemide Teva Italia. These products have been removed from the list of medicines recommended for suspension.

Key facts

About this medicine
Approved name
About this procedure
Current status
Opinion provided by Committee for Medicinal Products for Human Use
Reference number
Article 31 referrals

This type of referral is triggered when the interest of the Union is involved, following concerns relating to the quality, safety or efficacy of a medicine or a class of medicines.

Authorisation model
Nationally authorised product(s)
Decision making model
Key dates and outcomes
CHMP opinion date

All documents

Procedure started

Opinion provided by Committee for Medicinal Products for Human Use

Description of documents published

Please note that some of the listed documents apply only to certain procedures.

  • Overview - lay-language summary of the stage of the procedure
  • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
  • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
  • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
  • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
  • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
  • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
  • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
  • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
  • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
  • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
  • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
  • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
  • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
  • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

Note that older documents may have different titles.


How useful was this page?

Add your rating
1 rating
1 rating